Europe’s only weekly psychedelic medicine briefing.

Every Tuesday, 8am CET - the clinical, regulatory, and financing signals shaping European psychedelic medicine. Read by the investors and operators building the category. No hype. Just what moved.

Every Tuesday · 8am CET · Free.

A clinician, not a company, runs Germany's psilocybin compassionate use programme

Aug 18, 2026

•

10 min read

A clinician, not a company, runs Germany's psilocybin compassionate use programme

Twenty-seven of the 28 compassionate use programmes on the German register are run by a pharmaceutical company. The psilocybin entry names a university institute and one psychiatrist.

Dhruv Shekhawat

No European application on file for the world's most advanced psilocybin programme

Aug 4, 2026

•

7 min read

No European application on file for the world's most advanced psilocybin programme

Britain's assessment machinery is built to start before a licence exists. It has nothing to start on. Twelve analysts took questions on Compass's last earnings call, and not one asked about Europe.

Dhruv Shekhawat

Europe already pays for clinic-administered psychiatry. Just not for psychedelics.

Jul 28, 2026

•

6 min read

Europe already pays for clinic-administered psychiatry. Just not for psychedelics.

Lilly is recruiting depression patients in four EU countries while its psychedelic deal names no European milestone at all. The difference is not Europe. It is what Europe costs to enter for a scheduled drug, and what nobody has yet asked it to pay.

Dhruv Shekhawat

Eli Lilly buys AtaiBeckley for $3.8B, and prices Europe out of psychedelic medicine

Jul 21, 2026

•

6 min read

Eli Lilly buys AtaiBeckley for $3.8B, and prices Europe out of psychedelic medicine

Eli Lilly bought AtaiBeckley for up to $3.8 billion and priced Europe at zero. Every regulatory milestone in the deal points at the FDA and the DEA. Not one points at the EMA.

Dhruv Shekhawat

Jul 14, 2026

•

5 min read

Issue 6 / Week of 7-13 July 2026

Europe finally has a date to prescribe psilocybin: the first half of 2027. The trial behind it compared the drug to itself.

Dhruv Shekhawat

Jul 7, 2026

•

4 min read

Issue 5 / Week of 30 June-6 July 2026

European psychedelic depression development just split into two camps. The dividing line is whether patients have to quit their antidepressants first.

Dhruv Shekhawat

Europe’s only weekly psychedelic medicine briefing.

A clinician, not a company, runs Germany's psilocybin compassionate use programme

No European application on file for the world's most advanced psilocybin programme

Europe already pays for clinic-administered psychiatry. Just not for psychedelics.

Eli Lilly buys AtaiBeckley for $3.8B, and prices Europe out of psychedelic medicine

Issue 6 / Week of 7-13 July 2026

Issue 5 / Week of 30 June-6 July 2026

Subscribe for new reads…

Quick Links

Subscription

Socials